<DOC>
	<DOCNO>NCT00226473</DOCNO>
	<brief_summary>The purpose multicenter study examine whether propose randomize treatment regime result significantly longer survival time high quality life additionally applied multiple chemotherapy accord CVD- scheme . So far neither establish treatment regime reliable data exist second-line chemotherapy metastatic malignant melanoma . Patients therefore mostly treat single multiple chemotherapeutics or/and immunomodulatory therapeutic . These regime however imply often high toxicity show rarely response rate high 10 % .</brief_summary>
	<brief_title>Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy Metastasized Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<criteria>histological diagnosis metastatic melanoma ( stage IV ) progressive disease firstline chemotherapy immunochemotherapy Karnofskyindex &gt; 60 % informed consent Uvea melanoma another primary malignancy except basal cell carcinoma cervical carcinoma situ severe and/or uncontrolled medical disease ( diabetes mellitus , cardiac insufficiency )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>malignant Melanoma</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Metastasis</keyword>
	<keyword>standard palliative care</keyword>
	<keyword>best supportive care</keyword>
</DOC>